SCHEMBL7606231

SCHEMBL7606231

N#Cc1cccc(NS(=O)(=O)c2cncn2-c2ncc(C(F)(F)F)cc2I)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 2/20 0.46
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
KMT2A Q03164 1/20 0.38
SCN10A Q9Y5Y9 1/20 0.36
TSHR P16473 1/20 0.36
CCR9 P51686 2/20 0.35
IDH1 O75874 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PIK3CA P42336 1/20 0.35
ALDH1A1 P00352 1/20 0.34
MCL1 Q07820 1/20 0.34
PKM P14618 1/20 0.34
VNN1 O95497 1/20 0.34
TP53 P04637 1/20 0.34
CCR6 P51684 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
SLC22A6 Q4U2R8 1/20 0.34
SLC22A8 Q8TCC7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL592895 0.89 ALDH1A1 (0.47) SLC22A12PTGS1PTGS2KMT2ACCR9
SCHEMBL7593843 0.78 PKM (0.59) SLC22A12PTGS1PTGS2KMT2ACCR9
SCHEMBL593033 0.77 ALDH1A1 (0.52) KMT2ATSHRL3MBTL1ALDH1A1PKM
SCHEMBL16205845 0.76 SLC22A12 (0.41) SLC22A12PTGS1PTGS2CCR9MCL1
SCHEMBL593506 0.76 ALDH1A1 (0.51) KMT2AIDH1L3MBTL1ALDH1A1PKM
SCHEMBL7590697 0.74 PKM (0.50) KMT2AL3MBTL1ALDH1A1PKM
SCHEMBL15542336 0.72 PKM (0.48) KMT2AALDH1A1PKMCYP2C9
SCHEMBL592360 0.72 PKM (0.52) PTGS1PTGS2KMT2AL3MBTL1ALDH1A1
SCHEMBL7606024 0.71 ALDH1A1 (0.49) KMT2AALDH1A1PKM
SCHEMBL594469 0.71 ALDH1A1 (0.49) KMT2ATSHRL3MBTL1ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122885-A1 PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE AGIOS PHARMACEUTICALS, INC. 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122885-A1 PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE PDK2, PDK1, PDK3 SLC22A12 2249/4885PTGS1 2007/4885PTGS2 1263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.